What's driving the future of biological specimen logistics?

Against the backdrop of explosive growth in the biopharmaceutical industry, the transportation of biological specimens, a key link connecting scientific research, clinical practice, and production, is undergoing a profound technological revolution. From gene editing to cell therapy, and from cross-border logistics to green and low-carbon initiatives, the industry is accelerating its evolution toward efficiency, safety, and sustainability, driven by the core forces of intelligence, specialization, and globalization. According to industry forecasts, the global biological specimen courier market is expected to reach $14.5 billion in 2025, with an annual growth rate of 17.2%. The Chinese market leads the world in growth rate.

Technological Intelligence: Full-Chain Digitalization Reshapes Industry Standards

• AI + Blockchain: Precise Traceability from Source to Endpoint

Dachenwei's AI biological specimen delivery box integrates satellite positioning, real-time temperature control (with an accuracy of ±2℃), and blockchain technology to achieve immutable data for the entire specimen chain, from collection to use. After being adopted by a top-tier hospital, the manual registration error rate approached zero, saving over hundreds of thousands of yuan in labor costs annually. Similarly, Thermo Fisher's intelligent temperature control system uses the Internet of Things (IoT) to monitor the transportation environment in real time, increasing the survival rate of cell-based pharmaceuticals during intercontinental transport from 85% to 98%.

• Predictive Maintenance: Dual Assurance of Equipment Health and Specimen Safety

Rendao Biobank's system trains an AI model to analyze historical data, allowing it to predict liquid nitrogen consumption cycles and automatically replenish stock, reducing equipment failure rates by more than 70%. Haier Biomedical's liquid nitrogen management system is even more advanced, having obtained FDA 21 CFR Part 11 certification, which ensures the credibility and traceability of electronic records. This has made it the "gold standard" for international clinical trials.

Market Specialization: Niche Demands Drive Customized Solutions

• Cold Chain Transportation: Technological Breakthroughs in Extreme Environment

The demand for transporting specimens at -80°C and below is growing at a rate of over 18%, driving companies to develop extreme-temperature-resistant packaging materials and smart devices. Advance International Corp. all-electric -196°C storage system can maintain an ultra-low-temperature environment without liquid nitrogen, reducing operating costs by 50%-90%. It can also maintain low temperatures for 10 days after a power outage. The hydrogel encapsulation technology, a collaboration between Manbo Bio and Atelerix from the UK, has made it possible to preserve cell specimens at room temperature for two weeks, completely subverting the traditional frozen logistics model.

• Cell Therapy Logistics: Cross-Border Collaboration and Regulatory Innovation

With the popularization of CAR-T and gene editing therapies, the demand for customized logistics has surged. Shanghai's pioneering cross-border cold chain network uses a "combination of air cold chain + liquid nitrogen tanks" solution to shorten cell transportation time from 7 days to 4. It also pioneered a "risk assessment + blockchain traceability" regulatory model, successfully completing the world's first cross-border CAR-T therapy. The biological specimen hub center, jointly built by KingMed Diagnostics and China Southern Logistics, has a "come and go" green channel that improves the transportation efficiency of specimens from remote areas by 30%.

Globalization and Compliance: From Regional Networks to International Standards

• International Certification and Strategic Mergers and Acquisitions

DHL acquired CRYOPDP to obtain international clinical trial transportation qualifications, while Haier Biomedical's active air temperature-controlled container earned the first FAA airworthiness certification in the Asia-Pacific region. This allows for precise temperature control of ±1°C and serves routes between China-Europe and China-US. Chinese companies are breaking the monopoly of European and American companies through technological breakthroughs. For example, Qingdao Honghu's temperature-controlled containers have completed intercontinental transportation tasks like "Shanghai-Chicago" and have gained widespread international market recognition.

• Regional Hubs and Multimodal Transport

Henan leverages its logistics hub advantages, with its cold chain logistics scale exceeding 120 billion yuan in 2024 and the number of refrigerated trucks ranking first in central China. Shanghai has built a nationwide cold chain network through its Pudong and Hongqiao dual hubs. Nanchang International Dry Port's "railway + cold chain" model has improved the transportation efficiency of Southeast Asian fruits by 30% and reduced cross-border logistics costs by 15%.

Sustainable Development: Green Technology and Resource Integration as Dual Drivers

• Eco-Friendly Materials and Energy-Saving Equipment

Youleng Technology's biosafety transport box uses fluorine-free polyurethane insulation material, which can be disinfected and reused. Alwin's electric drive system reduces carbon emissions by 90% compared to traditional liquid nitrogen solutions, making it a low-carbon benchmark for the industry. DNA/RNA Shield's room-temperature transportation technology, which inactivates pathogens and stabilizes nucleic acids, completely eliminates the need for dry ice and styrofoam, reducing annual landfill waste by over ten thousand tons.

• Mergers and Acquisitions and Cost Optimization

In 2024, SF Express acquired three regional logistics companies, reducing unit transportation costs by 12% through resource integration. JD Logistics reduced last-mile delivery costs by 20% through intelligent sorting and crowdsourced delivery. The penetration rate of new energy refrigerated vehicles has jumped from 19.3% in 2023 to 35.8% in 2025, with annual sales exceeding 10,000 units, making them the "main force" in cold chain transportation.

The biological specimen transportation industry is at the crossroads of intelligence and globalization. From cross-border collaboration in cell therapy to the global practice of green logistics, and from AI-driven precise traceability to the network layout of regional hubs, technological innovation and model transformation are reshaping the industry's ecosystem. In the future, with the rise of emerging fields such as gene therapy and synthetic biology, the industry will further delve into niche markets while gaining a more central position in the global value chain through international standard alignment and resource integration. As Wang Liancheng, General Manager of Haier Biomedical, said, "The Chinese solution is rewriting international rules, and the 'golden age' of biological Specimen Transportation has arrived."